Autologous CAR-transduced VSTs targeting TAAs such as CD30 (Hodgkin lymphoma), HER2 (glioblastoma), and GD2 (neuroblastoma and osteosarcoma) have been successfully manufactured and infused in early-phase clinical studies, demonstrating favorable safety and preliminary signs of efficacy [97,98,99]. Here, ERBB2 is linked to glioblastoma.